ComprehensiveInvitroandInsilicoAnalysis of Secondary Metabolites fromDatura metel: Promising Anti-Alzheimer’s Therapeutics

Abstract

AbstractThis research investigates secondary metabolites fromDatura metelas potential anti-Alzheimer’s therapies. In vitro techniques isolated extracts for AD pathology targeting, with in silico analysis identifying gene targets for prevention. Apigenin, Luteolin, and Withanolide A were studied, each with 300 potential gene targets and core gene counts of 54, 52, and 58 respectively. Lipinski’s Rule assessed their pharmacological properties, showing good absorption but limited blood-brain barrier penetration. Protein interaction mapping revealed shared targets among the compounds. GO enrichment and KEGG pathway analysis highlighted their impact on biological processes and pathways, suggesting their anti-Alzheimer’s potential. Luteolin notably reduced Aβ1–42 levels by up to 35.2% (*p<0.05) in SH-SY5Y cells, positioning it and Withanolide A as promising multi-functional Alzheimer’s medications. These findings underscore the significance of Datura phytochemicals in AD prevention and treatment.